VNL1 Stock Chart & Stats
€0.03
<€0.01(7.69%)
At close: 4:00 PM EST
€0.03
<€0.01(7.69%)
Day’s Range― - ―
52-Week Range€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)1.74K
Market Cap
€7.82M
Enterprise Value€52.71M
Total Cash (Recent Filing)€25.16M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-13.65
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding995,351,700
10 Day Avg. Volume4,000
30 Day Avg. Volume1,739
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.36
Price to Sales (P/S)4.69
P/FCF Ratio14.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetRecent years show no reported debt and a debt-to-equity ratio of zero, reducing mandatory financing costs and refinancing exposure. This conservative funding structure gives the company more flexibility to direct cash toward operations or recovery initiatives during a difficult earnings period.
Improved Cash GenerationPositive operating cash flow across 2023–2025 and positive free cash flow in 2024–2025 indicate improved cash discipline despite accounting losses. If sustained, internally generated cash can support ongoing operations and reduce reliance on external financing.
Higher Gross MarginThe substantial gross-margin improvement suggests stronger economics before operating expenses and provides a more favorable base for a potential recovery. Sustaining this improvement could increase the cash contribution from revenue, although operating-cost control remains necessary.
Bears Say
Persistent UnprofitabilityPersistent losses over 2022–2025 and a deeply negative TTM net margin show that the business has not yet converted revenue into sustainable earnings. Continued losses can consume equity, constrain reinvestment, and make any turnaround dependent on material operating improvement.
Shrinking Equity BaseMaterial equity erosion from 2021–2025 reflects the cumulative effect of repeated losses and weak returns on capital. A smaller capital base reduces financial resilience over time, while negative recent ROE indicates that shareholder resources are not currently generating productive returns.
Volatile Free Cash FlowAlthough recent cash flow improved, the sharp 2025 free-cash-flow decline and earlier periods of negative operating cash flow indicate inconsistent cash conversion. This volatility makes funding capacity less predictable and increases execution risk while profitability remains weak.
VNL1 FAQ
What was China Health Group Inc.’s price range in the past 12 months?
China Health Group Inc. lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is China Health Group Inc.’s market cap?
China Health Group Inc.’s market cap is €7.82M.
When is China Health Group Inc.’s upcoming earnings report date?
China Health Group Inc.’s upcoming earnings report date is Mar 30, 2027 which is in 157 days.
How were China Health Group Inc.’s earnings last quarter?
China Health Group Inc. released its earnings results on Aug 27, 2026. The company reported €0.001 earnings per share for the quarter.
Is China Health Group Inc. overvalued?
According to Wall Street analysts China Health Group Inc.’s price is currently Overvalued.
Does China Health Group Inc. pay dividends?
China Health Group Inc. does not currently pay dividends.
What is China Health Group Inc.’s EPS estimate?
China Health Group Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Health Group Inc. have?
China Health Group Inc. has 995,351,700 shares outstanding.
What happened to China Health Group Inc.’s price movement after its last earnings report?
China Health Group Inc. reported an EPS of €0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of China Health Group Inc.?
Currently, no hedge funds are holding shares in DE:VNL1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
China Health Group Inc.
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Technical Analysis
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
Biosino Bio-Technology & Science, Inc. Class H
―